Redefining prophylaxis in the modern era.

Autor: Mahlangu JN; Faculty of Health Sciences, Haemophilia Comprehensive Care, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and the NHLS, Johannesburg, South Africa., Blanchette V; Department of Pediatrics, Division of Hematology/Oncology Hospital for Sick Children, University of Toronto, Toronto, ON, Canada., Klamroth R; Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
Jazyk: angličtina
Zdroj: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Feb; Vol. 27 Suppl 3, pp. 21-27. Date of Electronic Publication: 2020 May 29.
DOI: 10.1111/hae.14035
Abstrakt: Prophylaxis is the globally accepted standard of care for persons with haemophilia and presents many advantages over episodic treatment. The prophylaxis benefits include bleed reduction, reduction in musculoskeletal complications and improvement in the quality of life. The currently evolving novel therapies for the management of haemophilia has ushered a new era characterized by improved prophylaxis targets and outcomes. These redefined targets and outcomes have necessitated the need to also redefine prophylaxis. In this state-of-the-art review, we redefine prophylaxis in the modern era by revisiting its definition, presenting data to support higher trough levels to achieve with prophylaxis and introducing steady-state haemostasis as a possible new target for prophylaxis.
(© 2020 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje